Becton Dickinson and (NYSE:BDX) released its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.41 by $0.07, Bloomberg Earnings reports. The firm had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. Becton Dickinson and’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $2.33 earnings per share. Becton Dickinson and updated its FY18 guidance to $10.85-11.00 EPS.
Becton Dickinson and (NYSE:BDX) traded down $5.50 during mid-day trading on Tuesday, reaching $213.39. The company had a trading volume of 461,466 shares, compared to its average volume of 1,647,288. Becton Dickinson and has a 12-month low of $175.66 and a 12-month high of $248.39. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. The stock has a market cap of $50,220.00, a price-to-earnings ratio of 167.09, a P/E/G ratio of 1.49 and a beta of 1.12.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s payout ratio is currently 229.01%.
A number of research firms recently issued reports on BDX. Morgan Stanley lifted their target price on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price target for the company in a report on Friday, January 19th. Bank of America reaffirmed a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a report on Friday, January 19th. Finally, Citigroup upgraded Becton Dickinson and from a “sell” rating to a “neutral” rating in a research report on Friday, January 5th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $237.27.
In related news, Director Timothy M. Ring sold 269,661 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the sale, the director now owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.00% of the stock is currently owned by corporate insiders.
Several institutional investors have recently modified their holdings of BDX. Koch Industries Inc. increased its holdings in shares of Becton Dickinson and by 45,268.7% during the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock worth $1,391,000 after buying an additional 1,395,182 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Becton Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after buying an additional 1,353,780 shares during the last quarter. Winslow Capital Management LLC acquired a new stake in shares of Becton Dickinson and during the 2nd quarter worth $225,164,000. Janus Henderson Group PLC increased its holdings in shares of Becton Dickinson and by 1,265.9% during the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock worth $236,245,000 after buying an additional 1,122,191 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Becton Dickinson and by 6.0% during the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock worth $4,026,750,000 after buying an additional 1,071,288 shares during the last quarter. 75.56% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Becton Dickinson and (BDX) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/13/becton-dickinson-and-bdx-releases-quarterly-earnings-results-beats-expectations-by-0-07-eps.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.